AN2 Therapeutics 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, we're going to go ahead and get started. I'm Steve. We are on the dosing curve in PV patients. We know what that looks like extensively in non-PV patients over long periods of time. We'll start at a 250 milligram once a day oral, very simple.
Patients start, these are phlebotomy control patients, so they start below 45% hematocrit, and our aim here is just to keep them there. They're having multiple phlebotomies once a month, once every other month. We want to be able to maintain their hematocrits below 45%. That part is you can start at a dose. If you need a little more, then you can step up after a month to the next higher dose, 500, and then 750 after that. We think we'll find the dose within that. 250 may be perfectly fine for most patients, or they may need a little more. We don't know. Then we'll analyze that data. The main purpose of that part one is just to see, do all these observational data that we see, does that translate into PV? Do we have a drug here?
What's the dose? Then we go into a part two where we randomize patients. They stay on their dose or they go to placebo and see if it returns to baseline if they're on placebo. We incorporate PROs on how they're feeling when they go off drug. There'll just be more convincing data, but not necessary for a phase III design that we have. Then there's an extension, part three, that we would have after that.
Okay. That gives you durability data.
So it sounds like these are patients who have hematocrit sub 45, some baseline level of phlebotomies. It kind of sounds like this is going to look like a lot of the other proof of concept phase II trials that we've seen Yes in this space.
From an efficacy benchmarking perspective, this should give you a pretty clear answer, correct?
Yeah. Yeah, I think so.
Okay. How are you thinking just about the cadence of data disclosures that we should expect to see from this trial throughout the course of next year? Maybe you can also speak to kind of the amount and the type of data that we should expect to see with kind of maybe the first couple of disclosures.
Yeah. We are planning to start the first patient dose this year. We think that around the first quarter, we should have that first 10 patients sentinel through month one and be able to read that out. But then those same patients are going to start rolling into part one, and around mid-year, they will be at the 28-week or so timeframe. We think that there's potential, once we have enough patients out long enough that we can say that we're reducing phlebotomies or holding patients' hematocrit, then we'd have a data cut. We look at some of the competitive programs like rusfertide.
The announced date after seven patients. They had patients between 28 weeks and four weeks. Somewhere in the 10-15 patient range over a course of time, we'll do a data cut. We want to get this out to the markets and to us. It's an open-label trial, so we're going to know what's going on and get these data. Then we'll have just kind of a sequence of data cuts over time, whether we present at ASH or some of these conferences, things like that.
Okay. Mid-year to third quarter, I think we'll start having, like, does this drug work in PV like it's intended?
Okay. Yeah, PV has become a very active development landscape. You mentioned rusfertide that just received FDA approval. There's a number of other hepcidin-modulating therapies that are, I guess, entering late-stage development, and one of which was just the focal point of a fairly sizable M&A transaction. How do you think about the opportunity to establish competitive differentiation with the epetraborole relative to some of those other therapies that are in phase II?
Yeah, I think first and foremost, from what we hear back from key opinion leaders and so forth is, epetraborole is oral, so all those therapies are injectable, number one. Two is, it's a different mechanism of action. We know, kind of the effect occurs in late-stage erythrocytes, but we think it's on the globin side, and all those agents affect iron starvation and kind of the heme side of the equation. So it's a different MOA, which allows you opportunities to look at combinations or different things to control hematocrit. Three is, it seems to be exquisitely red blood cell focused, so it doesn't have much effect on platelets, it doesn't have any effect on white blood cells or precursors, so it seems to be red cell specific, which is highly desirable.
If all those things happen, I think it seems like it's got a very broad use case relative to some of those agents.
Okay. Yeah. Yeah, I think some of the leukocytosis and thrombocytosis we've seen with those drugs is still kind of an interesting work in progress.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
